Saturday 17 October 2026
Export MPLT’s income statement to Excel — free account
MapLight Therapeutics, Inc.
MPLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.6% and free cash flow fell 31.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.70
0.32
−3.99%
Follow MPLT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 12.24 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 21.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 109 | 133 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | (78) | (161) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | — | (78) | (161) | |||||
| Depreciation | — | — | — | — | — | — | — | — | (1) | (2) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | (105.38) | (18.56) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (107.06) | (15.91) | |||||
| Capex | — | — | — | — | — | — | — | — | (1.05) | (0.05) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (108.10) | (15.97) | |||||
| Book value | — | — | — | — | — | — | — | — | (263.01) | 52.80 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (79) | (138) | ||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (80) | (139) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 99 | 308 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | (109) | (305) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (194) | 458 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (52.29) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (68.95) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (121.74) | |||||
Negative figures in brackets.
Charts ten years each
MapLight Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics PLC Sponsored ADR | $457.8M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| OCS Oculis Holding AG | $456.8M | — (loss-making) | — (loss-making) | +23.96% (above 0%: growing) | n/m | −10.40% (below 0%: shrinking) | 100.00% | (7,603.42%) | Compare |
| EPRX Eupraxia Pharmaceuticals Inc. | $446.2M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | Compare |
| MPLT MapLight Therapeutics, Inc. | $445.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | |
| OVID Ovid Therapeutics | $441.4M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| PROK ProKidney Corp. | $439.9M | — (loss-making) | — (loss-making) | −32.13% (below 0%: shrinking) | n/m | −28.03% (below 0%: shrinking) | 100.00% | (32,248.67%) | Compare |
| INDP Indaptus Therapeutics, Inc. | $437.7M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PRTA Prothena Corporation plc | $436.4M | — (loss-making) | 188× | −77.15% (below 0%: shrinking) | n/m | +44.64% (above 0%: growing) | 100.00% | (2,089.21%) | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $433.6M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $440.6M | — | — | +23.96% | — | −8.57% | 100.00% | (1,092.58%) |
MapLight Therapeutics, Inc. (MPLT) key facts
- MapLight Therapeutics, Inc. (MPLT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MPLT traded at $7.70, a market capitalization of $445.7 million.
- Return on equity was −121.7% and debt-to-equity 0.00.